A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors

Basit Öğe Kaydı
dc.contributor.authorInanc, Guezide Nevsun
dc.contributor.authorTerzioglu, Mustafa Ender
dc.contributor.authorKarabulut, Yusuf
dc.contributor.authorYilmaz, Zevcet
dc.contributor.authorTarhan, Emine Figen
dc.contributor.authorEnecik, Mehmet Emin
dc.contributor.authorSahin, Ali
dc.date.accessioned2024-10-26T18:00:44Z
dc.date.available2024-10-26T18:00:44Z
dc.date.issued2023
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractBackground/aim: To describe the disease activity and retention rate in rheumatoid arthritis (RA) patients with inadequate response (IR) to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and/or tumor necrosis factor inhibitors (TNFis) who were prescribed tocilizumab (TCZ) as first-line or second-line biologic treatment in real-world setting.Materials and methods: Data gathered from patients' files was used in a multicenter and retrospective context. Retention rates and the Disease Activity Score in 28 joints with CRP (DAS28-CRP) were evaluated at time points. The relationship of drug efficacy with factors such as smoking, obesity, and previous use of TNFis was also examined.Results: One hundred and twenty-four patients with a median (IQR) RA duration of 3.7 (7.4) years were included. Mean (SD) age was 52.9 (12.9) and 75% of the patients were female. TCZ retention rates in the 6th and 12th months were 94.1% and 86.6%, respectively. In all patients, DAS28-CRP level decreased significantly from baseline to Months 3 and 6. There was an increase in patients with remission and/or low disease activity and a decrease in patients with high disease activity at Month 3 and Month 6 (p < 0.001 for both). Disease activity was similar between subgroups based on body mass index, smoking status, and previous use of TNFis at any time point. Regres-sion analysis showed that absence of concomitant corticosteroid treatment independently was associated with remission/LDA achieve-ment at Month 6 [OR = 0.31, 95% CI (0.14- 0.72), p = 0.006], and Month 12 [OR = 0.35, 95% CI (0.13-0.94), p = 0.037]. Overall, 25 mild adverse events were reported.Conclusion: TCZ was found to be effective and safe in RA patients with IR to csDMARDs and/or TNFis. The drug retention rate was considered satisfactory with more than half of the patients continuing TCZ treatment at Month 12.
dc.description.sponsorshipRoche Mustahzarlari San AS., Turkey
dc.description.sponsorshipThe study was funded by Roche Mustahzarlari San AS., Turkey in accordance with Good Publication Practice (GPP3) guidelines. All authors contributed to the conduction and writing of this study and have approved the final version.& nbsp;
dc.identifier.doi10.55730/1300-0144.5636
dc.identifier.endpage743
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue3
dc.identifier.pmid37476902
dc.identifier.scopus2-s2.0-85163656306
dc.identifier.scopusqualityQ3
dc.identifier.startpage731
dc.identifier.trdizinid1191045
dc.identifier.urihttps://doi.org/10.55730/1300-0144.5636
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1191045
dc.identifier.urihttps://hdl.handle.net/20.500.12418/27837
dc.identifier.volume53
dc.identifier.wosWOS:001022334700013
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTubitak Scientific & Technological Research Council Turkey
dc.relation.ispartofTurkish Journal of Medical Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectRheumatoid arthritis
dc.subjectanti-interleukin-6
dc.subjecttocilizumab
dc.titleA national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu